Fibrocell Science to Present at BioCentury NewsMakers of the Biotech Industry Conference

BioCentury Conference 2014

EXTON, Pa.--()--Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer of Fibrocell Science will present at the BioCentury NewsMakers in the Biotech Industry conference at 9:30 a.m. EDT on Friday, September 26, 2014, in New York City. Mr. Pernock will discuss the company’s autologous fibroblast technology, and its therapeutic candidates in development focused on genetically-modified personalized biologics.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (NASDAQ:FCSC) is an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Based on its proprietary autologous fibroblast technology, Fibrocell is pursuing breakthrough medical applications of azficel-T for restrictive burn scarring and vocal cord scarring. The company’s collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, includes using genetically-modified fibroblasts for treating orphan skin diseases for which there are no currently approved products. For additional information, visit www.fibrocellscience.com.

Contacts

Investor Relations:
S.A. Noonan Communications, LLC
Susan Noonan, 212-966-3650
susan@sanoonan.com

Fibrocell Science, Inc.